Santral Retinal Ven Tıkanıklığı ve Maküla Ödeminde Patogenez

KAYMAZ, Abdulgani; Ulas, Fatih; Uyar, Enes

Santral Retinal Ven Tıkanıklığı ve Maküla Ödeminde Patogenez

Fatih ULAŞ, (Bolu Abant İzzet Baysal Üniversitesi)

Enes UYAR, (Aksaray Eğitim ve Araştırma Hastanesi)

Abdulgani KAYMAZ (Bolu Abant İzzet Baysal Üniversitesi)

Güncel Retina Dergisi

6 0

Yıl: 2019 Cilt: 3 Sayı: 1 Sayfa Aralığı: 11 - 17 Metin Dili: Türkçe İndeks Tarihi: 28-11-2019

Santral Retinal Ven Tıkanıklığı ve Maküla Ödeminde Patogenez

Öz:

Santral retinal ven tıkanıklığı (SRVT) yaygın görülen bir retinal vasküler hastalıktır. Fakat SRVT patogenezi tam olarakbilinmemektedir. SRVT gelişiminde çeşitli sistemik ve lokal risk faktörleri rol oynamaktadır. SRVT maküler ödem (MÖ) veneovaskülarizasyona neden olarak görmeyi olumsuz etkileyebilmektedir. MÖ, maküler bölgede sıvı ve protein birikmesi sonucuoluşmaktadır. MÖ patofizyolojisi oldukça karmaşık bir süreçtir ve MÖ gelişiminde birçok faktör etkili olmaktadır. Bu derlemedeSRVT ve SRVT nedeniyle oluşan MÖ patogenezi tartışılmıştır.

Anahtar Kelime:

Konular: Cerrahi

Pathogenesis of Central Retinal Vein Obstruction and Macular Edema

Öz:

Central retinal vein occlusion (CRVO) is a common retinal vascular disorder. However, the exact pathogenesis of CRVO is not known. Various local and systemic factors play role in development of CRVO. CRVO might cause visual morbidity, including macular edema (ME) and neovascularization. ME occurs when fluid and protein deposits accumulate in the macular region. The pathophysiology of ME is complex, with a variety of processes involved in its development. The pathogenesis of CRVO and ME is discussed in the current review.

Anahtar Kelime:

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Bibliyografik

1. McAllister IL. Central retinal vein occlusion: a review. Clin Exp Ophthalmol, 2012; 40(1): 48-58.
2. London NJ, Brown G. Update and review of central retinal vein occlusion. Curr Opin Ophthalmol, 2011; 22(3): 159-165.
3. Gewaily D, Muthuswamy K, Greenberg PB. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev, 2015; (9): CD007324.
4. Ip M, Hendrick A. Retinal Vein Occlusion Review. Asia Pac J Ophthalmol (Phila), 2017.
5. Ho M, Liu DT, Lam DS, Jonas JB. Retinal Vein Occlusions, from Basics to the Latest Treatment. Retina, 2016; 36(3): 432-448.
6. Kolar P. Risk factors for central and branch retinal vein occlusion: a metaanalysis of published clinical data. J Ophthalmol, 2014; 2014: 724780.
7. Liu Q, Lahey JM, Karlen R, Stewart JM. Laboratory Evaluation of Hypercoagulable States in Patients with Central Retinal Vein Occlusion Who Are Less Than 56 Years of Age. Retina, 2017.
8. Bradshaw SE, Gala S, Nanavaty M, Shah A, Mwamburi M, Kefalas P. Systematic literature review of treatments for management of complications of ischemic central retinal vein occlusion. BMC Ophthalmol, 2016; 16: 104.
9. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol, 2008; 126(4): 513-518.
10. Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol, 2006; 124(5): 726-732.
11. Mohamed Q, McIntosh RL, Saw SM, Wong TY. Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology, 2007; 114(3): 507-519, 524.
12. Garweg JG, Zandi S. Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex(R)) in its treatment. Graefes Arch Clin Exp Ophthalmol, 2016; 254(7): 1257-1265.
13. Hayreh SS, Zimmerman MB, Beri M, Podhajsky P. Intraocular pressure abnormalities associated with central and hemicentral retinal vein occlusion. Ophthalmology, 2004; 111(1): 133-141.
14. Stem MS, Talwar N, Comer GM, Stein JD. A longitudinal analysis of risk factors associated with central retinal vein occlusion. Ophthalmology, 2013; 120(2): 362-370.
15. Risk factors for central retinal vein occlusion. The Eye Disease Case- Control Study Group. Arch Ophthalmol, 1996; 114(5): 545-554.
16. Glacet-Bernard A, Leroux les Jardins G, Lasry S, Coscas G, Soubrane G, Souied E, Housset B. Obstructive sleep apnea among patients with retinal vein occlusion. Arch Ophthalmol, 2010; 128(12): 1533-1538.
17. Chou KT, Huang CC, Tsai DC, Chen YM, Perng DW, Shiao GM, Lee YC, Leu HB. Sleep apnea and risk of retinal vein occlusion: a nationwide population-based study of Taiwanese. Am J Ophthalmol, 2012; 154(1): 200- 205 e201.
18. Ehlers JP, Fekrat S. Retinal vein occlusion: beyond the acute event. Surv Ophthalmol, 2011; 56(4): 281-299.
19. Fong AC, Schatz H. Central retinal vein occlusion in young adults. Surv Ophthalmol, 1993; 37(6): 393-417.
20. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Progress in retinal and eye research, 2005; 24(4): 493-519.
21. Klien BA. Occlusion of the central retinal vein; clinical importance of certain histopathologic observations. Am J Ophthalmol, 1953; 36(3): 316-324.
22. Verhoeff FH. Visual phenomena associated with central scotoma caused by obstruction of the central retinal vein. Arch Ophthalmol, 1966; 75(4): 467- 468.
23. Hayreh SS. t-PA in CRVO. Ophthalmology, 2002; 109(10): 1758-1761; author reply 1761-1753.
24. Green WR, Chan CC, Hutchins GM, Terry JM. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc, 1981; 79: 371-422.
25. Fortunato P, Pollazzi L, Baroni M, Evangelisti A, La Torre A. Venous retinal flow reperfusion mechanisms following radial optic neurotomy with adjunctive intraocular triamcinolone in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol, 2010; 248(2): 167-173.
26. Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost, 2010; 8(9): 1886-1894.
27. MacDonald D. The ABCs of RVO: a review of retinal venous occlusion. Clin Exp Optom, 2014; 97(4): 311-323.
28. Hayreh SS, van Heuven WA, Hayreh MS. Experimental retinal vascular occlusion. I. Pathogenesis of central retinal vein occlusion. Arch Ophthalmol, 1978; 96(2): 311-323.
29. Prisco D, Marcucci R, Bertini L, Gori AM. Cardiovascular and thrombophilic risk factors for central retinal vein occlusion. Eur J Intern Med, 2002; 13(3): 163-169.
30. Elman MJ, Bhatt AK, Quinlan PM, Enger C. The risk for systemic vascular diseases and mortality in patients with central retinal vein occlusion. Ophthalmology, 1990; 97(11): 1543-1548.
31. O’Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol, 2008; 126(5): 692-699.
32. Rath EZ, Frank RN, Shin DH, Kim C. Risk factors for retinal vein occlusions. A case-control study. Ophthalmology, 1992; 99(4): 509-514.
33. Zhou JQ, Xu L, Wang S, Wang YX, You QS, Tu Y, Yang H, Jonas JB. The 10-year incidence and risk factors of retinal vein occlusion: the Beijing eye study. Ophthalmology, 2013; 120(4): 803-808.
34. Jonas JB, Mones J, Glacet-Bernard A, Coscas G. Retinal Vein Occlusions. Dev Ophthalmol, 2017; 58: 139-167.
35. Paton A, Rubinstein K, Smith VH. Arterial insufficiency in retinal venous occlusion (a short symposium). Trans Ophthalmol Soc U K, 1964; 84: 559-595.
36. Fujino T, Curtin VT, Norton EW. Experimental central retinal vein occlusion. A comparison of intraocular and extraocular occlusion. Arch Ophthalmol, 1969; 81(3): 395-406.
37. Kang MH, Balaratnasingam C, Yu PK, Morgan WH, McAllister IL, Cringle SJ, Yu DY. Alterations to vascular endothelium in the optic nerve head in patients with vascular comorbidities. Exp Eye Res, 2013; 111: 50-60.
38. Kang MH, Balaratnasingam C, Yu PK, Morgan WH, McAllister IL, Cringle SJ, Yu DY. Morphometric characteristics of central retinal artery and vein endothelium in the normal human optic nerve head. Invest Ophthalmol Vis Sci, 2011; 52(3): 1359-1367.
39. Williamson TH. A “throttle” mechanism in the central retinal vein in the region of the lamina cribrosa. Br J Ophthalmol, 2007; 91(9): 1190-1193. 40. Williamson TH. Central retinal vein occlusion: what’s the story? Br J Ophthalmol, 1997; 81(8): 698-704.
41. Channa R, Smith M, Campochiaro PA. Treatment of macular edema due to retinal vein occlusions. Clin Ophthalmol, 2011; 5: 705-713.
42. Sinawat S, Bunyavee C, Ratanapakorn T, Sinawat S, Laovirojjanakul W, Yospaiboon Y. Systemic abnormalities associated with retinal vein occlusion in young patients. Clin Ophthalmol, 2017; 11: 441-447.
43. Klein BE, Meuer SM, Knudtson MD, Klein R. The relationship of optic disk cupping to retinal vein occlusion: the Beaver Dam Eye Study. Am J Ophthalmol, 2006; 141(5): 859-862.
44. Hayreh SS, Pe’er J, Zimmerman MB. Morphologic changes in chronic high-pressure experimental glaucoma in rhesus monkeys. J Glaucoma, 1999; 8(1): 56-71.
45. Fegan CD. Central retinal vein occlusion and thrombophilia. Eye (Lond), 2002; 16(1): 98-106.
46. Gao W, Wang YS, Zhang P, Wang HY. Hyperhomocysteinemia and low plasma folate as risk factors for central retinal vein occlusion: a case-control study in a Chinese population. Graefes Arch Clin Exp Ophthalmol, 2006; 244(10): 1246-1249.
47. Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost, 2005; 93(6): 1021-1026.
48. Lahey JM, Kearney JJ, Tunc M. Hypercoagulable states and central retinal vein occlusion. Curr Opin Pulm Med, 2003; 9(5): 385-392.
49. Lahey JM, Tunc M, Kearney J, Modlinski B, Koo H, Johnson RN, Tanaka S. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Ophthalmology, 2002; 109(1): 126-131.
50. Linna T, Ylikorkala A, Kontula K, Puska P, Tervo T. Prevalence of factor V Leiden in young adults with retinal vein occlusion. Thromb Haemost, 1997; 77(1): 214-216.
51. Narayanasamy A, Subramaniam B, Karunakaran C, Ranganathan P, Sivaramakrishnan R, Sharma T, Badrinath VS, Roy J. Hyperhomocysteinemia and low methionine stress are risk factors for central retinal venous occlusion in an Indian population. Invest Ophthalmol Vis Sci, 2007; 48(4): 1441-1446.
52. Kuhli C, Hattenbach LO, Scharrer I, Koch F, Ohrloff C. High prevalence of resistance to APC in young patients with retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol, 2002; 240(3): 163-168.
53. Kuhli-Hattenbach C, Scharrer I, Luchtenberg M, Hattenbach LO. Coagulation disorders and the risk of retinal vein occlusion. Thromb Haemost, 2010; 103(2): 299-305.
54. Rehak M, Krcova V, Slavik L, Fric E, Langova K, Ulehlova J, Rehak J. The role of thrombophilia in patients with retinal vein occlusion and no systemic risk factors. Can J Ophthalmol, 2010; 45(2): 171-175.
55. Rehak M, Rehak J, Muller M, Faude S, Faude F, Siegemund A, Krcova V, Slavik L, Hasenclever D, Scholz M, Wiedemann P. The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis. Thromb Haemost, 2008; 99(5): 925-929.
56. Rehak M, Muller M, Scholz M, Wiercinska J, Niederwieser D, Wiedemann P. [Antiphospholipid syndrome and retinal vein occlusion. Metaanalysis of Published Studies]. Ophthalmologe, 2009; 106(5): 427-434.
57. Ingerslev J. Thrombophilia: a feature of importance in retinal vein thrombosis? Acta Ophthalmol Scand, 1999; 77(6): 619-621.
58. Sofi F, Mannini L, Marcucci R, Bolli P, Sodi A, Giambene B, Menchini U, Gensini GF, Abbate R, Prisco D. Role of haemorheological factors in patients with retinal vein occlusion. Thromb Haemost, 2007; 98(6): 1215-1219.
59. Trope GE, Lowe GD, McArdle BM, Douglas JT, Forbes CD, Prentice CM, Foulds WS. Abnormal blood viscosity and haemostasis in long-standing retinal vein occlusion. Br J Ophthalmol, 1983; 67(3): 137-142.
60. Williamson TH, Rumley A, Lowe GD. Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol, 1996; 80(3): 203-208.
61. Francis PJ, Stanford MR, Graham EM. Dehydration is a risk factor for central retinal vein occlusion in young patients. Acta Ophthalmol, 2003; 81(4): 415-416.
62. Alexander P, Flanagan D, Rege K, Foss A, Hingorani M. Bilateral simultaneous central retinal vein occlusion secondary to hyperviscosity in Waldenstrom’s macroglobulinaemia. Eye (Lond), 2008; 22(8): 1089-1092.
63. Avashia JH, Fath DF. Bilateral central retinal vein occlusion in Waldenstrom’s macroglobulinemia. J Am Optom Assoc, 1989; 60(9): 657-658.
64. Daruich A, Matet A, Moulin A, Kowalczuk L, Nicolas M, Sellam A, Rothschild PR, Omri S, Gelize E, Jonet L, Delaunay K, De Kozak Y, Berdugo M, Zhao M, Crisanti P, Behar-Cohen F. Mechanisms of macular edema: Beyond the surface. Prog Retin Eye Res, 2018; 63: 20-68.
65. Scholl S, Augustin A, Loewenstein A, Rizzo S, Kupperman B. General pathophysiology of macular edema. Eur J Ophthalmol, 2011; 21 Suppl 6: S10- 19.
66. Spaide RF. RETINAL VASCULAR CYSTOID MACULAR EDEMA: Review and New Theory. Retina, 2016; 36(10): 1823-1842.
67. Chiquet C, Bron AM, Straub M, Dupuy C, Isaico R, Aptel F, Creuzot- Garcher C. Retinal Vein Occlusions: Therapeutic Switch in Macular Oedema Treatment with a 12-Month Follow-Up. Ophthalmic Res, 2016; 55(3): 152-158.
68. Takeyama M, Takeuchi F, Gosho M, Sugita K, Zako M, Iwaki M, Kamei M. Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes. Clin Ophthalmol, 2018; 12: 35-41.
69. Klaassen I, Van Noorden CJ, Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res, 2013; 34: 19-48.
70. Omri S, Omri B, Savoldelli M, Jonet L, Thillaye-Goldenberg B, Thuret G, Gain P, Jeanny JC, Crisanti P, Behar-Cohen F. The outer limiting membrane (OLM) revisited: clinical implications. Clin Ophthalmol, 2010; 4: 183-195.
71. Ascaso FJ, Huerva V, Grzybowski A. The role of inflammation in the pathogenesis of macular edema secondary to retinal vascular diseases. Mediators Inflamm, 2014; 2014: 432685.
72. Drechsler F, Koferl P, Hollborn M, Wiedemann P, Bringmann A, Kohen L, Rehak M. Effect of intravitreal anti-vascular endothelial growth factor treatment on the retinal gene expression in acute experimental central retinal vein occlusion. Ophthalmic Res, 2012; 47(3): 157-162.
73. Noma H, Funatsu H, Mimura T, Harino S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology, 2009; 116(1): 87-93.
74. Vinores SA, Derevjanik NL, Ozaki H, Okamoto N, Campochiaro PA. Cellular mechanisms of blood-retinal barrier dysfunction in macular edema. Doc Ophthalmol, 1999; 97(3-4): 217-228.
75. Gu X, Fliesler SJ, Zhao YY, Stallcup WB, Cohen AW, Elliott MH. Loss of caveolin-1 causes blood-retinal barrier breakdown, venous enlargement, and mural cell alteration. Am J Pathol, 2014; 184(2): 541-555.
76. Xu H, Dawson R, Crane IJ, Liversidge J. Leukocyte diapedesis in vivo induces transient loss of tight junction protein at the blood-retina barrier. Invest Ophthalmol Vis Sci, 2005; 46(7): 2487-2494.
77. Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, Zlabinger GJ, Schmidt-Erfurth U. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci, 2009; 50(3): 1025-1032.
78. Koss MJ, Pfister M, Rothweiler F, Michaelis M, Cinatl J, Schubert R, Koch FH. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol, 2012; 90(2): e98-e103.
79. Jung SH, Kim KA, Sohn SW, Yang SJ. Association of aqueous humor cytokines with the development of retinal ischemia and recurrent macular edema in retinal vein occlusion. Invest Ophthalmol Vis Sci, 2014; 55(4): 2290- 2296.
80. Kida T. Mystery of Retinal Vein Occlusion: Vasoactivity of the Vein and Possible Involvement of Endothelin-1. Biomed Res Int, 2017; 2017: 4816527.
81. Coscas F, Glacet-Bernard A, Miere A, Caillaux V, Uzzan J, Lupidi M, Coscas G, Souied EH. Optical Coherence Tomography Angiography in Retinal Vein Occlusion: Evaluation of Superficial and Deep Capillary Plexa. Am J Ophthalmol, 2016; 161: 160-171 e161-162.
82. Spaide RF. Volume-Rendered Optical Coherence Tomography of Retinal Vein Occlusion Pilot Study. Am J Ophthalmol, 2016; 165: 133-144.
83. Schnitzer J. Retinal astrocytes: their restriction to vascularized parts of the mammalian retina. Neurosci Lett, 1987; 78(1): 29-34.
84. Willermain F, Libert S, Motulsky E, Salik D, Caspers L, Perret J, Delporte C. Origins and consequences of hyperosmolar stress in retinal pigmented epithelial cells. Front Physiol, 2014; 5: 199.
85. Chatziralli I, Theodossiadis G, Chatzirallis A, Parikakis E, Mitropoulos P, Theodossiadis P. RANIBIZUMAB FOR RETINAL VEIN OCCLUSION: Predictive Factors and Long-Term Outcomes in Real-Life Data. Retina, 2018; 38(3): 559-568.
86. Bringmann A, Pannicke T, Grosche J, Francke M, Wiedemann P, Skatchkov SN, Osborne NN, Reichenbach A. Muller cells in the healthy and diseased retina. Prog Retin Eye Res, 2006; 25(4): 397-424.
87. Iandiev I, Pannicke T, Biedermann B, Wiedemann P, Reichenbach A, Bringmann A. Ischemia-reperfusion alters the immunolocalization of glial aquaporins in rat retina. Neurosci Lett, 2006; 408(2): 108-112.
88. Pannicke T, Iandiev I, Uckermann O, Biedermann B, Kutzera F, Wiedemann P, Wolburg H, Reichenbach A, Bringmann A. A potassium channel-linked mechanism of glial cell swelling in the postischemic retina. Mol Cell Neurosci, 2004; 26(4): 493-502.
89. Iandiev I, Tenckhoff S, Pannicke T, Biedermann B, Hollborn M, Wiedemann P, Reichenbach A, Bringmann A. Differential regulation of Kir4.1 and Kir2.1 expression in the ischemic rat retina. Neurosci Lett, 2006; 396(2): 97-101.
90. Stamer WD, Bok D, Hu J, Jaffe GJ, McKay BS. Aquaporin-1 channels in human retinal pigment epithelium: role in transepithelial water movement. Invest Ophthalmol Vis Sci, 2003; 44(6): 2803-2808.

APA	Ulas F, Uyar E, KAYMAZ A (2019). Santral Retinal Ven Tıkanıklığı ve Maküla Ödeminde Patogenez. , 11 - 17.
Chicago	Ulas Fatih,Uyar Enes,KAYMAZ Abdulgani Santral Retinal Ven Tıkanıklığı ve Maküla Ödeminde Patogenez. (2019): 11 - 17.
MLA	Ulas Fatih,Uyar Enes,KAYMAZ Abdulgani Santral Retinal Ven Tıkanıklığı ve Maküla Ödeminde Patogenez. , 2019, ss.11 - 17.
AMA	Ulas F,Uyar E,KAYMAZ A Santral Retinal Ven Tıkanıklığı ve Maküla Ödeminde Patogenez. . 2019; 11 - 17.
Vancouver	Ulas F,Uyar E,KAYMAZ A Santral Retinal Ven Tıkanıklığı ve Maküla Ödeminde Patogenez. . 2019; 11 - 17.
IEEE	Ulas F,Uyar E,KAYMAZ A "Santral Retinal Ven Tıkanıklığı ve Maküla Ödeminde Patogenez." , ss.11 - 17, 2019.
ISNAD	Ulas, Fatih vd. "Santral Retinal Ven Tıkanıklığı ve Maküla Ödeminde Patogenez". (2019), 11-17.

APA	Ulas F, Uyar E, KAYMAZ A (2019). Santral Retinal Ven Tıkanıklığı ve Maküla Ödeminde Patogenez. Güncel Retina Dergisi, 3(1), 11 - 17.
Chicago	Ulas Fatih,Uyar Enes,KAYMAZ Abdulgani Santral Retinal Ven Tıkanıklığı ve Maküla Ödeminde Patogenez. Güncel Retina Dergisi 3, no.1 (2019): 11 - 17.
MLA	Ulas Fatih,Uyar Enes,KAYMAZ Abdulgani Santral Retinal Ven Tıkanıklığı ve Maküla Ödeminde Patogenez. Güncel Retina Dergisi, vol.3, no.1, 2019, ss.11 - 17.
AMA	Ulas F,Uyar E,KAYMAZ A Santral Retinal Ven Tıkanıklığı ve Maküla Ödeminde Patogenez. Güncel Retina Dergisi. 2019; 3(1): 11 - 17.
Vancouver	Ulas F,Uyar E,KAYMAZ A Santral Retinal Ven Tıkanıklığı ve Maküla Ödeminde Patogenez. Güncel Retina Dergisi. 2019; 3(1): 11 - 17.
IEEE	Ulas F,Uyar E,KAYMAZ A "Santral Retinal Ven Tıkanıklığı ve Maküla Ödeminde Patogenez." Güncel Retina Dergisi, 3, ss.11 - 17, 2019.
ISNAD	Ulas, Fatih vd. "Santral Retinal Ven Tıkanıklığı ve Maküla Ödeminde Patogenez". Güncel Retina Dergisi 3/1 (2019), 11-17.